Saturday, 31 October 2026European Markets

VGP And FIDUCIAL REAL EST. Have A High Dividend Yield And Return On Equity In The Real Estate Services Industry.

Loading stream...

(vianews) - vgp (vgp.br) is among this list of stock assets with the highest dividend rate and return on equity on the real estate services industry.

financial asset price forward dividend yield return on equity
vgp (vgp.br) €94.70 3.19% 8.79%
fiducial real est. (oria.pa) €181.00 1.86% 6.67%

several euronext companies pay out dividends to its shareholders. the dividend yield is a dividend to price ratio showing how much a company pays out in dividends each year.

1. vgp (vgp.br)

3.19% forward dividend yield and 8.79% return on equity

vgp nv, together with its subsidiaries, develops, owns, and manages logistics and semi-industrial real estate, and ancillary offices. it leases its properties to tenants in the logistic sector, including storing, assembling, re-conditioning, and final treatment of the goods. the company also provides property management services; asset management services related to corporate administration, financing, business planning, reporting, budgeting, management of tax and legal affairs, controlling, etc.; project management and leasing services; and facility management services, such as maintenance, waste management, and greenery maintenance services. it operates in germany, spain, france, italy, the netherlands, austria, portugal, the czech republic, slovakia, hungary, romania, serbia, and latvia. vgp nv was founded in 1998 and is headquartered in antwerp, belgium.

earnings per share

as for profitability, vgp has a trailing twelve months eps of €3.2.

pe ratio

vgp has a trailing twelve months price to earnings ratio of 29.59. meaning, the purchaser of the share is investing €29.59 for every euro of annual earnings.

return on equity

the company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is 8.79%.

volume

today's last reported volume for vgp is 4589 which is 63.1% below its average volume of 12438.

yearly top and bottom value

vgp's stock is valued at €94.70 at 22:40 est, way below its 52-week high of €114.80 and way above its 52-week low of €73.10.

more news about vgp.

2. fiducial real est. (oria.pa)

1.86% forward dividend yield and 6.67% return on equity

fiducial real estate sa operates and manages real estate properties in france. its property portfolio includes office, business, and residential buildings. the company is headquartered in courbevoie, france.

earnings per share

as for profitability, fiducial real est. has a trailing twelve months eps of €12.43.

pe ratio

fiducial real est. has a trailing twelve months price to earnings ratio of 14.56. meaning, the purchaser of the share is investing €14.56 for every euro of annual earnings.

return on equity

the company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is 6.67%.

dividend yield

as maintained by morningstar, inc., the next dividend payment is on may 15, 2024, the estimated forward annual dividend rate is 3.3 and the estimated forward annual dividend yield is 1.86%.

volume

today's last reported volume for fiducial real est. is 1 which is 88.88% below its average volume of 9.

yearly top and bottom value

fiducial real est.'s stock is valued at €181.00 at 22:40 est, below its 52-week high of €190.00 and higher than its 52-week low of €170.00.

moving average

fiducial real est.'s value is above its 50-day moving average of €176.38 and above its 200-day moving average of €178.57.

more news about fiducial real est..

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
ESMO 2026 Oncology Data Wave Builds Toward Ivonescimab PDUFA, While Micro-Cap Biotech Exits the Market
Late October 2026 is a dense catalyst window led by ESMO 2026. Daiichi Sankyo's DXd antibody-drug conjugate (ADC) programs (DESTINY-Lung04, DESTINY-Breast11, REJOICE-Ovarian01/02, TUXEDO-3), Guardant's 25 abstracts and the PACE-LUNG ctDNA trial all report there. These feed into the FDA's 14 November 2026 PDUFA date for ivonescimab. Large and mid-cap developers with late-stage data and commercial launches (ZEGFROVY, ANKTIVA, MIUDELLA, lorundrostat, duvakitug) are drawing capital and attention. Spago Nanomedical's board decision to seek a Nasdaq First North delisting (EGM 19 November, application 25 January 2027) shows the capital squeeze on early-stage, single-asset names (Tumorad is Phase I).
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
Ford Motor Company
Both facts give cash for Ford Motor Company at the same point in time (2025-12-31; FY 2025 year-end and Q4 2025 year-end are the same date). Both are labelled USD, but the values are 23,356,000,000 and 23.356, which cannot both be true in USD. The two numbers agree once the second is read as billions (23.356 bn = 23,356,000,000), so the economic content is consistent and the conflict is a unit/scale error in the Q4 2025 record. The period is not the reason for the conflict: a Q4 and an FY figure at the same year-end date should match.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,994
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,994 facts checked against source5,514 source documents archived
Query this data → isubstrate.com